Publications by authors named "David A Potter"

Claim this Profile
E
Endothelial dysfunction in breast cancer survivors on aromatase inhibitors: changes over time.
Adnan Shaaban, Ashley Petersen, Heather Beckwith, Natalia Florea, David A Potter

Cardiooncology· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial-Efficacy and Biomarker Discovery.
Kathy S Albain, Christina Yau, Emanuel F Petricoin, Denise M Wolf, Julie E Lang, David A Potter

Clin Cancer Res· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cooling inflammation while potentiating immune checkpoint inhibition: Enhancing the benefit-risk ratio of immuno-oncology therapy.
David A Potter, Zhijun Guo, Jianxun Lei, Emmanuel S Antonarakis

Proc Natl Acad Sci U S A· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Endothelial Dysfunction in Breast Cancer Survivors on Aromatase Inhibitors: Changes over Time.
Adnan Shaaban, Ashley Petersen, Heather Beckwith, Natalia Florea, David A Potter

Res Sq· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lymphadenopathy after the third Covid-19 vaccine.
Can Özütemiz, David A Potter, Ayça Özbek Özütemiz, Daniel Steinberger

Curr Probl Cancer Case Rep· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Neoadjuvant Chemotherapy Trial for Early Breast Cancer is Impacted by COVID-19: Addressing Vaccination and Cancer Trials Through Education, Equity, and Outcomes.
David A Potter, Alexandra Thomas, Hope S Rugo

Clin Cancer Res· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sapanisertib Plus Exemestane or Fulvestrant in Women with Hormone Receptor-Positive/HER2-Negative Advanced or Metastatic Breast Cancer.
Bora Lim, David A Potter, Mohamad A Salkeni, Paula Silverman, Tufia C Haddad

Clin Cancer Res· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Recent advances in neoadjuvant therapy for breast cancer.
David A Potter, César A Herrera-Ponzanelli, Diego Hinojosa, Rafael Castillo, Irwin Hernandez-Cruz

Fac Rev· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Erratum: Author Correction: Surgical Standards for Management of the Axilla in Breast Cancer Clinical Trials with Pathological Complete Response Endpoint.
Judy C Boughey, Michael D Alvarado, Rachael B Lancaster, W Fraser Symmans, Rita Mukhtar, David A Potter

NPJ Breast Cancer· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting cytochrome P450-dependent cancer cell mitochondria: cancer associated CYPs and where to find them.
Zhijun Guo, Veronica Johnson, Jaime Barrera, Mariel Porras, Diego Hinojosa, David A Potter

Cancer Metastasis Rev· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Surgical Standards for Management of the Axilla in Breast Cancer Clinical Trials with Pathological Complete Response Endpoint.
Judy C Boughey, Michael D Alvarado, Rachael B Lancaster, W Fraser Symmans, Rita Mukhtar, David A Potter

NPJ Breast Cancer· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Erratum to: Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial.
Javier Cortés, Hope S Rugo, Ahmad Awada, Chris Twelves, Edith A Perez, David A Potter

Breast Cancer Res Treat· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Heme Binding Biguanides Target Cytochrome P450-Dependent Cancer Cell Mitochondria.
Zhijun Guo, Irina F Sevrioukova, Ilia G Denisov, Xia Zhang, Ting-Lan Chiu, David A Potter

Cell Chem Biol· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Heme Binding Biguanides Target Cytochrome P450-Dependent Cancer Cell Mitochondria.
Zhijun Guo, Irina F Sevrioukova, Ilia G Denisov, Xia Zhang, Ting-Lan Chiu, David A Potter

Cell Chem Biol· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial.
Javier Cortés, Hope S Rugo, Ahmad Awada, Chris Twelves, Edith A Perez, David A Potter

Breast Cancer Res Treat· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health-related quality of life in patients with locally recurrent or metastatic breast cancer treated with etirinotecan pegol versus treatment of physician's choice: Results from the randomised phase III BEACON trial.
Chris Twelves, Javier Cortés, Joyce O'Shaughnessy, Ahmad Awada, Edith A Perez, David A Potter

Eur J Cancer· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Etirinotecan pegol (NKTR-102) versus treatment of physician's choice in women with advanced breast cancer previously treated with an anthracycline, a taxane, and capecitabine (BEACON): a randomised, open-label, multicentre, phase 3 trial.
Edith A Perez, Ahmad Awada, Joyce O'Shaughnessy, Hope S Rugo, Chris Twelves, David A Potter

Lancet Oncol· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Metformin Treatment for the Prevention and/or Treatment of Breast/Mammary Tumorigenesis.
Michael E Grossmann, Da-Qing Yang, Zhijun Guo, David A Potter, Margot P Cleary

Curr Pharmacol Rep· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CYP1A1 regulates breast cancer proliferation and survival.
Mariangellys Rodriguez, David A Potter

Mol Cancer Res· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Should diabetic women with breast cancer have their own intervention studies?
David A Potter, Douglas Yee, Zhijun Guo, Mariangellys Rodriguez

Endocr Relat Cancer· February 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prediction of postoperative recurrence-free survival in non-small cell lung cancer by using an internationally validated gene expression model.
Ranjana Mitra, Jinseon Lee, Jisuk Jo, Monica Milani, Jeanette N McClintick, David A Potter

Clin Cancer Res· May 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CYP3A4 mediates growth of estrogen receptor-positive breast cancer cells in part by inducing nuclear translocation of phospho-Stat3 through biosynthesis of (±)-14,15-epoxyeicosatrienoic acid (EET).
Ranjana Mitra, Zhijun Guo, Monica Milani, Clementina Mesaros, Mariangellys Rodriguez, David A Potter

J Biol Chem· May 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The human immunodeficiency virus protease inhibitor ritonavir inhibits lung cancer cells, in part, by inhibition of survivin.
Anjaiah Srirangam, Monica Milani, Ranjana Mitra, Zhijun Guo, Mariangellys Rodriguez, David A Potter

J Thorac Oncol· April 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anastrozole Use in Early Stage Breast Cancer of Post-Menopausal Women.
Monica Milani, Gautam Jha, David A Potter

Clin Med Ther· March 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gene silencing for epidermal growth factor receptor variant III induces cell-specific cytotoxicity.
Farnaz Yamoutpour, Vidya Bodempudi, Shay E Park, Weihong Pan, Mary Jean Mauzy, David A Potter

Mol Cancer Ther· November 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis